The global burden of chronic urticaria for the patient and society
M Gonçalo, A Gimenéz‐Arnau… - British Journal of …, 2021 - academic.oup.com
Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and
middle‐aged women. It usually lasts for several years (> 1 year in 25–75% of patients) and …
middle‐aged women. It usually lasts for several years (> 1 year in 25–75% of patients) and …
[HTML][HTML] The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management
M Sánchez-Borges, IJ Ansotegui, I Baiardini… - World Allergy …, 2021 - Elsevier
This is Part 1 of an updated follow-up review of a World Allergy Organization (WAO) position
paper published in 2012 on the diagnosis and treatment of urticaria and angioedema. Since …
paper published in 2012 on the diagnosis and treatment of urticaria and angioedema. Since …
Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany
Background Comprehensive data on the epidemiology and comorbidities of chronic urticaria
(CU) in Germany are either limited, or not contemporary. Objectives To investigate the …
(CU) in Germany are either limited, or not contemporary. Objectives To investigate the …
Antihistamine‐resistant chronic spontaneous urticaria remains undertreated: 2‐year data from the AWARE study
M Maurer, C Costa, AM Gimenez Arnau… - Clinical & …, 2020 - Wiley Online Library
Background Real‐world evidence describing the benefits of recommended therapies and
their impact on the quality of life (QoL) of chronic urticaria (CU) patients is limited. Objective …
their impact on the quality of life (QoL) of chronic urticaria (CU) patients is limited. Objective …
[HTML][HTML] Risk of comorbidities in patients diagnosed with chronic urticaria: A nationwide registry-study
MN Ghazanfar, L Kibsgaard, SF Thomsen… - World Allergy …, 2020 - Elsevier
Background The autoimmune profile of Chronic Urticaria (CU) patients is an increasing topic
of interest. Associated diseases suggest shared pathogenic pathways, and they may provide …
of interest. Associated diseases suggest shared pathogenic pathways, and they may provide …
[HTML][HTML] Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results
Abstract Background A Worldwide Antihistamine-Refractory Chronic Urticaria (CU) patient
Evaluation (AWARE) is a non-interventional, multicenter study including patients from …
Evaluation (AWARE) is a non-interventional, multicenter study including patients from …
Comorbidities of Chronic Urticaria: A glimpse into a complex relationship
N Papapostolou, P Xepapadaki, A Katoulis… - Frontiers in …, 2022 - frontiersin.org
Chronic Urticaria (CU) is a chronic inflammatory, predominantly mast cell-driven disease,
characterized by the development of wheals and/or angioedema for more than 6 weeks. It …
characterized by the development of wheals and/or angioedema for more than 6 weeks. It …
Omalizumab in chronic spontaneous urticaria (CSU): real-life experience in dose/interval adjustments and treatment discontinuation
R Brás, C Costa, R Limão, LE Caldeira… - The Journal of Allergy …, 2023 - Elsevier
Background Data on real-life experience with omalizumab dose/interval adjustments are still
limited, as well as on omalizumab discontinuation. Objective To evaluate efficacy and safety …
limited, as well as on omalizumab discontinuation. Objective To evaluate efficacy and safety …
Forewarned is forearmed: chronic spontaneous urticaria as a potential risk to effective SARS‐CoV‐2 vaccine uptake and global public health
WH Bermingham, MR Ardern‐Jones… - British Journal of …, 2021 - academic.oup.com
Chronic spontaneous urticaria and angio-oedema (CSU/A) is a common condition with an
estimated global point prevalence of 047%(95% confidence interval 042–144). 1 The …
estimated global point prevalence of 047%(95% confidence interval 042–144). 1 The …